

**DANAPHA PHARMACEUTICAL
JOINT STOCK COMPANY**

REVIEWED INTERIM FINANCIAL STATEMENTS
For the six-month period ended 30 June 2026

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

CONTENTS

	Page(s)
THE GENERAL DIRECTOR'S REPORT	1 - 2
REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION	3 - 4
REVIEWED INTERIM FINANCIAL STATEMENTS	
Interim financial position statement	5 - 6
Interim income statement	7
Interim cash-flow statement	8
Notes to the interim financial statements	9 - 46

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

THE GENERAL DIRECTOR'S REPORT

The General Director of Danapha Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") hereby presents its report and the accompanying reviewed interim financial statements of the Company for the six-month period ended 30 June 2026.

Members of the Board of Directors, the Supervisory Committee and the General Director during the period and on the date of this report include:

Board of Directors

<u>Full name</u>	<u>Position</u>	
Mr. Bojinov Stefan Georgiev	Chairman	Reappointed on 31 March 2026
Mr. Dobrev Sasho Hristov	Member	Reappointed on 31 March 2026
Mr. Le Thang Binh	Member	Reappointed on 31 March 2026
Mr. Do Minh Hieu	Member	Reappointed on 31 March 2026
Ms. Nguyen Thanh Thao	Independent Member	Reappointed on 31 March 2026
Ms. Nguyen Thi Thuy	Member	Reappointed on 31 March 2026
Ms. Ha Lan Anh	Member	Reappointed on 31 March 2026
Ms. Do Thi Thuy	Independent Member	Reappointed on 31 March 2026

Supervisory Committee

<u>Full name</u>	<u>Position</u>	
Mr. Ngo Xuan Tung	Head	Reappointed on 31 March 2026
Ms. Nguyen Thi Yen Nhi	Member	Reappointed on 31 March 2026
Ms. Luu Quynh Mai	Member	Reappointed on 31 March 2026

The General Director

<u>Full name</u>	<u>Position</u>	
Mr. Le Thang Binh	The General Director	Reappointed on 31 March 2026

LEGAL REPRESENTATIVE

The legal representative of the Company during the period and on the date of this report is Mr. Le Thang Binh, The General Director.

RESPONSIBILITY OF THE GENERAL DIRECTOR

The Company's General Director is responsible for preparing the interim financial statements of each period which give a true and fair view of the interim financial position of the Company and the results of its operations and its cash flows. In preparing these interim financial statements, the General Director is required to:

- Select suitable accounting policies and then apply them consistently;
- Make judgments and estimates that are reasonable and prudent;
- State whether applicable accounting principles have been followed, subject to any departures that need to be disclosed and explained in the interim financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and
- Design and implement the internal control system effectively for a fair preparation and presentation of the interim financial statements so as to mitigate error or fraud.

The General Director is responsible for ensuring that proper interim accounting records are kept, which disclose, with reasonable accuracy at any time, the interim financial position of the Company and ensure that the interim financial statements comply with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of the interim

THE GENERAL DIRECTOR'S REPORT (CONTINUED)

financial statements. The General Director is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The General Director confirms that the Company has complied with the above requirements in preparing these interim financial statements.

AUDITOR

The accompanying interim financial statements were reviewed by ECOVIS AFA VIETNAM Auditing – Appraisal and Consulting Company Limited (Head office: No. 142 Xo Viet Nghe Tinh Street, Hoa Cuong Ward, Danang City, Vietnam; Telephone: (84) 0236.363.3333; Fax: (84) 0236.363.3338; Website: www.ecovis.com/vietnam/audit).

STATEMENT BY THE GENERAL DIRECTOR

In the General Director's opinion, the accompanying interim financial statements give a true and fair view of the interim financial position of the Company as at 30 June 2026 and the results of its interim operations and its interim cash flows for the six-month accounting period then ended in accordance with the Vietnamese Accounting Standards, Vietnamese Corporate Accounting System and the statutory requirements relevant to the preparation and presentation of the interim financial statements.



Le Thang Binh
General Director

Danang City, 14 August 2026

No.: 351/2026/BCSX-E.AFA

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To: Shareholders
Board of Directors and The General Director
DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

We have reviewed the accompanying interim financial statements of Danapha Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") prepared on 14 August 2026 as set out from page 5 to page 46, which comprise the interim financial position statement as at 30 June 2026, and the interim income statement, and interim cash-flow statement for the six-month period then ended, and notes to the interim financial statements.

The General Director's Responsibility

The General Director is responsible for the preparation and fair presentation of these interim financial statements in accordance with Vietnamese Accounting Standards, and Vietnamese Corporate Accounting System and relevant legislation as to the preparation and presentation of interim financial statements and for such internal control as Management determines is necessary to enable the preparation and presentation of the interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility


Our responsibility is to express a conclusion on these interim financial statements based on our review. We conducted our review in accordance with the Vietnamese Standards on Review Engagements 2410- Review of Interim Financial Information Performed by Independent Auditor of the Entity.

A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, applying analytical procedures and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION (CONTINUED)

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim financial statements do not give a true and fair view, in all material respects, of the interim financial position of the Company as at 30 June 2026, and of its interim financial performance and its interim cash flows for the six-month period then ended in accordance with Vietnamese Accounting Standards and Vietnamese Corporate Accounting System and relevant legislation as to the preparation and presentation of interim financial statements.



Kim Van Viet

Deputy General Director

Audit Practice Registration Certificate

No. 1486-2023-240-1

Authorized person

ECOVIS AFA VIETNAM Auditing – Appraisal and Consulting Company Limited

Danang City, 14 August 2026

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

Form B 01a - DN(Issued under the Circular No. 99/2025/TT-BTC
dated 27 October 2025 by Ministry of Finance)**INTERIM STATEMENT OF FINANCIAL POSITION**

As at 30 June 2026

Unit: VND

ASSETS	Code	Notes	As at 30 Jun. 2026	As at 01 Jan. 2026
A. CURRENT ASSETS	100		533,390,169,415	657,862,535,833
I. Cash and cash equivalents	110	4.1	61,543,873,956	68,991,415,929
1. Cash	111		7,126,041,548	68,991,415,929
2. Cash equivalents	112		54,417,832,408	-
II. Current financial investments	120		-	-
III. Current account receivables	130		281,461,247,311	432,752,858,144
1. Trade receivables	131	4.2	245,077,342,185	383,006,079,436
2. Advances to suppliers	132	4.3	50,077,151,262	59,307,731,730
3. Other current receivables	135	4.4	7,276,550,225	6,379,279,372
4. Provision for doubtful debts	136	4.5	(20,969,796,362)	(15,940,232,394)
IV. Inventories	140	4.6	167,633,580,793	129,759,756,781
1. Inventories	141		171,504,056,981	134,948,701,888
2. Provision for decline in value of inventories	142		(3,870,476,188)	(5,188,945,107)
V. Current biological assets	150		-	-
VI. Other current assets	160		22,751,467,355	26,358,504,979
1. Current deferred expenses	161	4.7	4,771,924,638	2,321,643,660
2. Value added tax deductible	162		17,970,413,836	24,036,861,319
3. Tax and other receivables from the state budget	163	4.15	9,128,881	-
B. NON-CURRENT ASSETS	200		1,580,596,592,268	1,523,136,621,640
I. Non-current account receivables	210		-	-
II. Fixed assets	220		811,345,623,659	95,705,685,342
1. Tangible fixed assets	221	4.9	776,564,474,683	60,459,260,810
Cost	222		1,110,257,488,352	375,127,961,896
Accumulated depreciation	223		(333,693,013,669)	(314,668,701,086)
2. Intangible fixed assets	227	4.10	34,781,148,976	35,246,424,532
Cost	228		48,689,386,013	48,689,386,013
Accumulated amortisation	229		(13,908,237,037)	(13,442,961,481)
III. Non - current biological assets	230		-	-
IV. Investment property	240		-	-
V. Non-current assets in progress	250		747,210,842,355	1,405,425,618,051
1. Non-current work in progress	251		-	-
2. Construction in progress	252	4.11	747,210,842,355	1,405,425,618,051
VI. Non-current financial investments	260	4.8	6,800,000,000	6,800,000,000
1. Investments in associates, joint-ventures	262		8,820,000,000	8,820,000,000
2. Investment in other entities	263		6,800,000,000	6,800,000,000
3. Provision for non-current investments	264		(8,820,000,000)	(8,820,000,000)
VII. Other non-current assets	270		15,240,126,254	15,205,318,247
1. Non-current deferred expenses	271	4.7	15,240,126,254	15,205,318,247
2. Other non-current assets	274		-	-
TOTAL ASSETS	280		2,113,986,761,683	2,180,999,157,473

The accompanying notes are an integral part of these separate financial statements

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

Form B 01a - DN(Issued under the Circular No. 99/2025/TT-BTC
dated 27 October 2025 by Ministry of Finance)**INTERIM STATEMENT OF FINANCIAL POSITION (CONTINUED)**

As at 30 June 2026

Unit: VND

RESOURCES	Code	Notes	As at 30 Jun. 2026	As at 01 Jan. 2026
C. LIABILITIES	300		1,192,620,240,971	1,330,322,211,589
I. Current liabilities	310		682,172,177,948	516,317,754,059
1. Current trade payables	311	4.12	183,540,663,029	199,879,488,319
2. Current advances from customers	312	4.13	7,701,871,028	1,906,820,492
3. Dividends and profit distribution payable	313	4.14	10,090,920	10,090,920
4. Current taxes and amounts payable to the state budget	314	4.15	25,653,925,211	16,607,966,690
5. Payables to employees	315	4.16	23,124,594,413	32,408,028,038
6. Current accrued expenses	316	4.17	26,021,365,620	34,535,784,509
7. Other current payables	320	4.18	11,683,637,894	32,751,670,857
8. Current loans and obligations under finance leases	321	4.19	403,128,466,260	196,846,881,622
9. Bonus and welfare fund	323	4.20	1,307,563,573	1,371,022,612
II. Non-current liabilities	330		510,448,063,023	814,004,457,530
1. Non-current trade payables	331	4.12	217,784,327,145	328,383,111,022
2. Non-current loans and obligations under finance leases	339	4.19	292,417,136,083	480,985,536,083
3. Deferred income tax liabilities	342	4.21	246,599,795	4,635,810,425
D. OWNER'S EQUITY	400	4.22	921,366,520,712	850,676,945,884
1. Owner's contributed capital	411		209,380,000,000	209,380,000,000
Ordinary shares carrying voting rights	411a		209,380,000,000	209,380,000,000
Preference shares	411b		-	-
2. Capital surplus	412		181,169,607,584	181,169,607,584
3. Investment and development fund	418		460,127,338,300	374,134,185,572
4. Retained earnings	420		70,689,574,828	85,993,152,728
Beginning accumulated retained earnings	420a		-	243,600,000
Retained earnings of the current period	420b		70,689,574,828	85,749,552,728
TOTAL RESOURCES	440		2,113,986,761,683	2,180,999,157,473



Le Thang Binh
General Director
Danang City, 14 August 2026

Tran Tien Dung
Chief Financial Officer
Cum Chief Accountant

Nguyen Thi Thu Hang
Preparer

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

Form B 02a - DN(Issued under the Circular No. 99/2025/TT-BTC
dated 27 October 2025 by Ministry of Finance)**INTERIM INCOME STATEMENT**

For the six-month period ended 30 June 2026

Unit: VND

ITEMS	Code	Notes	Current period	Previous period
1. Revenue from selling goods and rendering services	01	5.1	329,028,284,223	295,997,578,093
2. Revenue deductions	02	5.2	2,575,781,083	1,378,070,622
3. Net revenue from selling goods and rendering services	10		326,452,503,140	294,619,507,471
4. Cost of sales	11	5.3	146,181,271,161	133,278,850,454
5. Gross profit from selling goods and rendering services	20		180,271,231,979	161,340,657,017
6. Profit/(Loss) from the sale and disposal of investment properties	21		-	-
7. Finance income	22	5.4	18,262,909,299	3,749,071,061
8. Finance expense	23	5.5	10,151,397,802	32,263,428,528
- Of which, borrowing costs	24		9,581,105,054	3,914,351,333
9. Selling expense	25	5.6	40,545,080,899	49,553,716,091
10. General and administration expense	26	5.7	57,814,496,133	53,223,190,595
11. Operating profit/(loss)	30		90,023,166,444	30,049,392,864
12. Other income	31	5.8	348,256,587	106,363,848
13. Other expense	32	5.9	163,566,816	67,791,615
14. Net other income/(loss)	40		184,689,771	38,572,233
15. Accounting profit/(loss) before taxation	50		90,207,856,215	30,087,965,097
16. Current corporate income tax expense	51	5.11	23,907,492,017	1,317,035,226
17. Deferred corporate income tax expense	52	5.12	(4,389,210,630)	4,225,027,793
18. Net profit/(loss) after taxation	60		70,689,574,828	24,545,902,078
19. Basic earnings per share	70	4.22.5	3,376	1,172
20. Diluted earnings per share	71	4.22.6	3,376	1,172



Le Thanh Binh
General Director
Danang City, 14 August 2026

(Signature)

Tran Tien Dung
Chief Financial Officer
Cum Chief Accountant

Nguyen Thi Thu Hang
Preparer

INTERIM CASH FLOW STATEMENT

(Indirect method)

For the six-month period ended 30 June 2026

Unit: VND

ITEMS	Code	Notes	Current period	Previous period
I. CASH FLOWS FROM OPERATING ACTIVITIES				
1. Net profit /(loss) before taxation	01		90,207,856,215	30,087,965,097
2. Adjustment for:				
Depreciation and amortisation	02		22,899,533,107	8,463,880,336
Provisions	03		3,711,095,049	3,017,137,771
Foreign exchange gains/losses from revaluation of foreign currency monetary items	04		(12,351,104,216)	28,007,403,556
Gains/losses from investment	05		(643,740,080)	(650,433,261)
Borrowing costs	06		9,581,105,054	3,914,351,333
3. Operating profit /(loss) before adjustments to working capital	08		113,404,745,129	72,840,304,832
Increase or decrease in accounts receivable	09		120,733,512,778	(25,579,783,667)
Increase or decrease in inventories	10		(36,555,355,093)	(20,905,050,239)
Increase or decrease in accounts payable (excluding interest expense and CIT payable)	11		(18,781,071,531)	(16,311,899,954)
Increase or decrease deferred expenses	12		(2,725,033,305)	84,157,098
Borrowing costs paid	14		(5,917,965,844)	(3,813,370,620)
Corporate income tax paid	15		(18,381,066,861)	(23,595,305,924)
Other cash inflows from operating activities	16		52,432,408	-
Other cash outflows from operating activities	17		(63,459,039)	(18,398,462)
Net cash from operating activities	20		151,766,738,642	(17,299,346,936)
II. CASH FLOWS FROM INVESTING ACTIVITIES				
1. Acquisition and construction of fixed assets and other long-term assets	21		(188,634,968,099)	(100,444,250,212)
2. Proceeds from disposals of fixed assets and other long-term assets	22		264,755,980	-
3. Interest and dividends received	27		326,551,692	887,849,329
Net cash from investing activities	30		(188,043,660,427)	(99,556,400,883)
III. CASH FLOWS FROM FINANCING ACTIVITIES				
1. Proceeds from borrowings	33	6.1	295,190,750,064	290,739,684,078
2. Repayment of borrowings	34	6.2	(265,485,065,426)	(172,547,679,763)
Net cash from financing activities	40		29,705,684,638	118,192,004,315
NET INCREASE/(DECREASE) IN CASH	50		(6,571,237,147)	1,336,256,496
Cash and cash equivalents at beginning of year	60		68,991,415,929	74,551,503,101
Impact of exchange rate fluctuation	61		(876,304,826)	2,113,234,266
CASH AND CASH EQUIVALENTS AT END OF PERIOD	70		61,543,873,956	78,000,993,863



Le Thang Binh
General Director
Danang City, 14 August 2026

Tran Tien Dung
Chief Financial Officer
Cum Chief Accountant

Nguyen Thi Thu Hang
Preparer

NOTES TO THE INTERIM FINANCIAL STATEMENTS

1. CORPORATE INFORMATION

1.1. Structure of ownership

Danapha Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") has been incorporated in accordance with the Business Registration Certificate No. 0400102091 dated 20 December 2006 granted by Danang City's Department of Planning and Investment and other amended certificates thereafter with the latest one dated 16 December 2025.

The charter capital as stipulated in the Business Registration Certificate is VND 209,380,000,000.

On 14 December 2021, the Company was formally licensed to trade securities on Hanoi Securities Trading Centre under Decision No. 703/QĐ-SGDHN dated 14 December 2021. On 22 December 2021, The company's shares are officially traded on the UPCOM market according to Notification No. 3654/TB-SGDHN dated 15 December 2021.

Pursuant to Appendix IV – Extraordinary Information Disclosure under Official Letter No. 759/DAN dated 10 July 2025, Danapha Pharmaceutical Joint Stock Company announced that it currently does not satisfy the conditions for being a public company as prescribed in Point a, Clause 1, Article 32 of the Law on Securities No. 54/2019/QH14, as amended and supplemented by Clause 1, Article 11 of Law No. 56/2024/QH15.

The Company's registered head office is at 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam.

The number of employees as at 30 June 2026 was 521 (31 December 2025: 521).

1.2. Business field

Manufacturing and trading pharmaceutical, chemical, and medicinal materials.

1.3. Operating industry and principal activities

Under the Business Registration Certificate, the Company's business activities comprise:

- Manufacture of pharmaceuticals, medicinal chemical and botanical product;
- Real estate activities with own or leased property;
- Retail sale of pharmaceutical and medical goods, cosmetic and toilet articles in specialized stores. Details: Retail sale of pharmaceutical and medical goods, cosmetics, and personal hygiene products;
- Manufacture of soap and detergents, cleaning and polishing preparations;
- Manufacture of other food products n.e.c. Details: Production of food and beverages;
- Wholesale of other household products. Details: Wholesale of medicines;
- Wholesale of food. Details: Wholesale of dietary supplements;
- Wholesale of other specialized goods not classified elsewhere. Details: Wholesale of pharmaceuticals, medicinal plants, packaging;
- Retail sales via mail and order houses or via Internet. Details: Retail of dietary supplements;
- Retail of food in specialized stores. Details: Retail of dietary supplements;
- Other professional, scientific, and technological activities not classified elsewhere. Details: Research and transfer of product formulas.

1.4. Normal operating cycle

The Company's normal operating cycle is carried out for a time period of 12 months.

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)**1.5. The Company's structure**

As at 30 June 2026, the Company's associates were as follows:

<u>Name</u>	<u>Address</u>	<u>Voting rights</u>	<u>Percent capital</u>	<u>Percent interest</u>
Associates:				
Davina Pharmaceutical Joint Stock Company	253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City.	49%	49%	49%

The Company's dependent units as at 30 June 2026 were as follows:

<u>Name</u>	<u>Address</u>
Branch of Danapha Pharmaceutical Joint Stock Company in Hanoi	No. 9, Lane 87 Nguyen Van Troi, Ward, Thanh Xuan Ward, Hanoi City.
Danapha Pharmaceutical Joint Stock Company – Vinh Phuc Branch	No. 43, Lot S6, Ha Tien pagoda Urban Area, Vinh Phuc Ward, Phu Tho Province.
Branch of Danapha Pharmaceutical Joint Stock Company in Thanh Hoa	Lot 141, LK3, MBQH121/UB-CN, Hac Thanh Ward, Thanh Hoa Province.
Branch of Danapha Pharmaceutical Joint Stock Company in Khanh Hoa	Lot 27-28, Street No. 8, Le Hong Phong New Urban Area - Venesia, Nam Nha Trang Ward, Khanh Hoa Province.
Branch of Danapha Pharmaceutical Joint Stock Company in Ho Chi Minh	15th Floor, Room 1508, Vincom Center Building, No. 72 Le Thanh Ton Street, Sai Gon Ward, Ho Chi Minh City.
Branch of Danapha Pharmaceutical Joint Stock Company in Can Tho	A3-22 Street No. 10, Nam Long Residential Area, Zone 2, Cai Rang Ward, Can Tho City.

2. BASIS OF PREPARATION**2.1. Accounting standards, accounting system**

The accompanying interim financial statements, expressed in Vietnamese Dong ("VND"), are prepared in accordance with Vietnamese Accounting Standards, Vietnamese Corporate Accounting System issued under Circular No. 99/2025/TT-BTC dated 27 October 2025 by the Ministry of Finance.

The accompanying interim financial statements are not intended to present the financial position, results of operations and cash flows in accordance with accounting principles and practices generally accepted in countries and jurisdictions other than Vietnam.

2.2. Forms of accounting records

The form of accounting records applied in the Company is the General Journal.

2.3. Accounting period

The Company's financial year is from 01 January to 31 December.

These interim financial statements are prepared for the six-month period ended on 30 June 2026.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

2.4. Reporting and functional currency

The Company maintains its accounting records in VND.

3. SIGNIFICANT ACCOUNTING POLICIES

3.1. Changes in accounting policies

The accounting policies applied by the Company in preparing the interim financial statements are consistently applied with those used in the preparation of the financial statements for the financial year ended 31 December 2025, except for the changes resulting from the adoption of new accounting guidance under Circular No. 99/2025/TT-BTC dated 27 October 2025, as presented below:

On 27 October 2025, the Ministry of Finance issued Circular No. 99/2025/TT-BTC ("Circular 99") providing guidance on the application of the Accounting System for Enterprises, which is effective from 01 January 2026 and applicable to financial years beginning on or after 1 January 2026. Circular 99 replaces the regulations on the Accounting System for Enterprises issued under Circular No. 200/2014/TT-BTC dated 22 December 2014, Circular No. 75/2015/TT-BTC dated 18 May 2015, Circular No. 53/2016/TT-BTC dated 21 March 2016 and Circular No. 195/2012/TT-BTC dated 15 November 2012 issued by the Ministry of Finance.

The Company has applied the changes in accounting policies prescribed under Circular 99 that affect the Company using the non-retrospective adjustment method in accordance with the guidance in Clause 1, Article 30 of Circular 99.

The Company has also restated the comparative information presented in the interim financial statements for certain line items to comply with the presentation requirements of Circular 99, as disclosed in Note 10.

3.2. Foreign currencies

Transactions in foreign currencies are recorded, on initial recognition, in the reporting currency, by applying to the foreign currency amount the spot exchange rate between the reporting currency and the foreign currency at the date of the transaction. The exchange differences arising on the settlement of monetary items are recognised in profit or loss in the year in which they arise. At the end of the reporting year, monetary items excluding advances to suppliers, prepaid expenses, and unearned revenues, which are denominated in foreign currency, are reported using the closing rate and resultant exchange differences resulting from the reporting after offset are recognised in profit or loss in the year in which they arise.

3.3. Use of estimates

The preparation of the interim financial statements requires management to make estimates and assumptions that impact the carrying value of certain assets and liabilities, contingent assets and liabilities reported in the notes as well as revenues and expenses for the six-month accounting period ended 30 June 2026. Although these estimates are based on management's best knowledge of all relevant information available at the date when the interim financial statements are prepared, this does not prevent actual figures differing from estimates.

3.4. Cash and cash equivalents

Cash and cash equivalents comprise cash in hand, cash at bank, cash in transit and current investments for a period not exceeding 3 months or highly liquid investments which are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

3.5. Financial investments

Held to maturity investments

Held to maturity investments comprise investments held to maturity with the objective of earning annual interest (such as term deposits at banks, valuable papers (including treasury bills, promissory notes and certificates of deposit), bonds, preference shares classified as liabilities, held to maturity loans) and other held to maturity investments.

At the end of the reporting period, if there is any reliable evidence that part or all of a held to maturity investment may be impaired, the impairment loss is recognised as finance expenses.

For held to maturity investments with discounts or premiums arising, such discounts or premiums are amortised gradually to finance income using the straight-line method over the term of the investment.

Equity investments in other entities

Investments in associates

Investments are classified as investments in associates when the Company directly or indirectly holds from 20% to under 50% of the voting shares of the investee without any other agreement.

Investments in associates are accounted for under the equity method. Under the equity method, on initial recognition the investment in an associate is recognised at cost. In case of investments of non-monetary assets, the cost of investments is recognised at the fair values of the assets as incurred.

Dividends for the period after the acquisition date are recognised as finance income when the shareholder's right to receive payment is established.

Other investments

Investments classified as other investments are investments other than investments in subsidiaries, investments in associates or investments on joint ventures.

Other investments are accounted for under the cost method which comprise purchase prices plus (+) acquisition related costs (if any). In case of investments of non-monetary assets, the cost of investments is recognised at the fair values of the assets as incurred.

Recognition principles of provision for investment impairment loss

Provision for investment impairment loss is made when there is any certain evidence that there will be an impairment in the value of these investments at the reporting date.

The difference between the required balance and the existing balance of provision for investment impairment loss is recognised as financial expenses in the income statement.

3.6. Account receivables

Recognition method

Account receivables are stated at the carrying amounts of trade receivables and other receivables less provisions for doubtful debts.

Provision for doubtful debts

As of the date of preparing the financial statements, provision for doubtful debt is recognised for past-due accounts receivable and for accounts receivable where circumstances indicate that they might not be recoverable when due at the level as guided in prevailing regulations. The determination of the overdue period of a doubtful receivable to be provisioned is based on the principal repayment period according to the original sale contract, excluding the debt extension between the parties.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

For overdue receivables, the provision rates are as follows:

- 30% of the value for receivables overdue from 6 months to less than 1 year;
- 50% of the value for receivables overdue from 1 year to less than 2 years;
- 70% of the value for receivables overdue from 2 years to less than 3 years;
- 100% of the value for receivables overdue for 3 years or more.

The difference between the required balance and the existing balance of provision for doubtful debts is recorded as a general and administrative expense in the income statement.

3.7. Inventories

Inventory measurement

Inventories are measured at the lower of cost and net realisable value.

The costs of inventories shall comprise all costs of purchase, costs of conversion, and other costs incurred in bringing inventories to their present location and condition. The cost of work in progress and finished goods includes materials, direct labour and attributable production overheads based on normal levels of activity.

The costs of purchase of inventories comprise the purchase price, non-reimbursable taxes and duties, and transport, handling and other costs directly attributable to the acquisition of inventories. Trade discounts and sales rebates on substandard and obsolete goods purchased are deducted from the costs of purchase.

Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Method of accounting for inventories

Inventories are measured using the weighted average method.

Provision for decline in value of inventories

As of the date of preparing the financial statements, provision is recognised for obsolete, slow-moving and defective inventory items and an excess of the cost of inventories over their net realisable value.

The difference between the required balance and the existing balance of the provision for a decline in value of inventories is included in cost of sales in the income statement.

Inventories are written down to net realizable value item by item. For services being rendered, provision is made in respect of each service for which a separate selling price is charged.

3.8. Tangible fixed asset

Tangible fixed assets are measured at cost less accumulated depreciation.

Tangible fixed asset recognition

Tangible fixed assets are initially recognised at their cost. The cost of purchased tangible fixed assets comprises the purchase price and any directly attributable costs of bringing the assets to their present location and working condition for their intended use. Accessories added to fixed assets when purchased are recognised separately at their fair value and deducted from the historical cost of the respective tangible fixed assets.

Depreciation and amortisation

The costs of fixed assets are depreciated on a straight-line method over their estimated useful lives.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

The estimated useful lives are as follows:

	<u>The first six months of 2026.</u>
▪ Buildings, structures	5 – 41 years
▪ Machinery and equipment	3 – 10 years
▪ Motor vehicles	6 – 10 years

3.9. Intangible fixed assets

Intangible fixed assets are measured at cost less accumulated amortisation.

Intangible fixed asset recognition

The cost of an intangible fixed asset comprises the total amount of expense incurred by the Company to acquire an asset at the time the asset is put into operation for its intended use.

Accounting principles for intangible fixed assets

Land use rights

Land use rights are stated at their costs less accumulated amortisation.

Indefinite land use rights are not amortised.

3.10. Leases

Operating leases

Lease payments under an operating lease are recognised as an expense on a straight-line basis over the lease term.

3.11. Construction in progress

Properties in the course of construction for production, rental or administrative purposes, or for purposes not yet determined, are carried at cost. Cost includes professional fees, and for qualifying assets, borrowing costs dealt with in accordance with the Group's accounting policy. Depreciation of these assets, on the same basis as other property assets, commences when the assets are ready for their intended use.

3.12. Deferred expenses

Deferred expenses are classified as current and non-current based on their original term. Deferred expenses mainly comprise land rentals, office rentals, repair expenses, insurances, etc.], which are amortised over the period in which economic benefits are generated in relation to these expenses.

The following expenses are recognised as deferred expenses and amortised to the income statement:

- Prepaid land, infrastructure and fixed asset rentals are amortised over the period of lease;
- Other prepaid expenses: Based on the nature and volume of each expense, the company selects appropriate methods and criteria for allocation during the period when the expected economic benefits are generated.

3.13. Liabilities

Liabilities are classified into trade payables, intra-company payables, dividends and profit payables and other payables based on the following rules:

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

- Trade payables represent those arising from purchase and sale related transactions of goods, services or assets and the seller is independent of the buyer;
- Dividends and profit payables are dividends and profits (in cash or non-monetary assets) payable to the shareholders of the Company;
- The remaining payables are classified as other payables.

Liabilities are also classified according to the maturity date, the remaining term from the date of the financial statements, original currency, and each creditor.

Liabilities are recognised at no less than the payment obligation.

3.14. Borrowing costs

Capitalisation of borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, that necessarily take a substantial period of time to get ready for their intended use or sale, are capitalised as part of the cost of those assets until the assets are put into use or sale.

Investment income earned on temporary investment of borrowings is deducted from the cost of the respective assets.

All other borrowing costs are recognised as an expense in the income statement when incurred.

3.15. Accrued expenses

Accrued expenses represent expenses that will be paid in the future for goods or services received but not yet paid due to lack of invoices or accounting documents. These expenses are recognised as operating expenses of the reporting period.

The company's accrued expenses include loan interest and sales commission expenses. Estimated loan interest expenses are calculated based on the outstanding loan balance and the interest rates specified in the credit agreements. Sales commission expenses are determined according to the sales policy applicable during each actual period.

3.16. Owners' equity

The owners' contributed equity

The owners' contributed equity is recognised when contributed.

Capital surplus

Capital surplus is recognised as the difference between the issue price and the par value of shares, the difference between the repurchase price of treasury shares and the reissue price of treasury shares sold, the value of the conversion option of convertible bonds into shares at the maturity date of the convertible bonds, and costs directly attributable to the issuance of shares.

Treasury shares

Treasury shares are recognised at purchased cost and presented in the statement of financial position as a deduction from equity.

Dividends

Dividends are recognised as a liability when the Company no longer has the right to refuse the obligation to pay dividends or profits in cash to shareholders.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

Retained earnings

Net profit after income tax can be distributed to shareholders after the distribution is approved the General annual meeting of shareholders and reserves are created in accordance with the Charter and legal regulations in Vietnam.

3.17. Revenue and other income

Revenue from selling goods

Revenue from selling goods is measured at the fair value of the consideration received or receivable. In most cases, revenue is recognised when transferring the risks and rewards of ownership to the buyer.

Revenue involving the rendering of services

Revenue of a transaction involving the rendering of services is recognised when the outcome of this transaction can be estimated reliably. When a transaction involving the rendering of services is attributable to several periods, each period's revenue is recognised by reference to the stage of completion at the end of the reporting period.

Interest income

Interest income is recognised on an accrual basis by reference to the principal outstanding and at the interest rate applicable.

Disposal and sale of investments

Revenue from selling current and non-current investments is recognised in the income statement when the Company has transferred the majority of risks and benefits associated with the ownership to the buyer. The majority of risks and benefits associated with the ownership are transferred to the buyer when the transaction is completed (for listed securities) or when completing the asset sale contract (for unlisted securities).

Disposal and sale of fixed assets, investment property

Income from disposal and sale of fixed assets, investment property is the excess of the proceeds from the disposal and sale of the fixed assets, investment property over the carrying amount of the fixed assets, investment property and disposal expenses.

3.18. Deductions

Deductions include trade discounts, allowances and sale returns.

Deductions arising in the reporting year from consumption of products, goods and services are recognised as decreases in revenue in that year; Deductions arising after the end of the reporting year but prior to issuing the financial statements for the reporting year are recognised as decreases in revenue of the reporting year; Deductions arising after the end of the reporting year and after issuing the financial statements for the reporting year are recognised as decreases in revenue of the next year.

3.19. Cost of sales

Cost of sales and services provided represents total costs of finished products, goods, services, investment properties or manufacturing costs of construction products (for construction entities) which are sold in the year in accordance with the matching principle. Abnormal amounts of production costs of inventories are recognised immediately in cost of sales.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

3.20. Finance expense

Finance expenses represent all expenses incurred in the reporting period which mainly include borrowing costs, losses from exchange rates, and provision for impairment of investment in other entities.

3.21. Selling expense and general and administrative expense

Selling expenses represent expenses incurred during the process of selling products, goods and rendering services, which include expenses relating to product exhibition, advertisement, sales commissions, product warranty (except for construction activities), storage, packaging and shipping etc.

General and administrative expenses represent common expenses, which include payroll costs for office employees' (salaries, wages, allowances, etc.); social insurance, health insurance, trade union fees and unemployment insurance; stationery expenses, material expenses, depreciation expenses of fixed assets used for administration activities; land rental, license tax; provision for doubtful debts; utility services (electricity expenses, water expenses, phone, fax, warranty expenses, etc.); sundry expenses (entertainment, customer conference, etc.).

3.22. Taxation

Corporate income tax

Current corporate income tax expense

Current corporate tax expense is determined on the basis of taxable income and the rate of corporate income tax (CIT) of the current year, as follows:

- The standard CIT rate applicable to the Company's ordinary manufacturing and business activities is 20%, in accordance with the prevailing tax regulations.
- Preferential CIT rate under Decree No. 04/2018/ND-CP dated 4 January 2018 on incentive mechanisms and policies applicable to the Da Nang Hi-Tech Park. Pursuant to this Decree, income derived from the Company's investment project located in the Da Nang Hi-Tech Park is entitled to a preferential CIT rate of 10% for a period of 15 years, together with a four-year CIT exemption and a 50% reduction of the CIT payable for the subsequent nine years, commencing from the period in which the project satisfies the conditions for enjoying the tax incentives in accordance with the CIT regulations. In March 2026, the Company commenced generating revenue from its manufacturing project located in the Da Nang Hi-Tech Park, Lien Chieu Ward, Da Nang City.

During the period, where the Company incurs tax losses from one business activity, such losses may be offset against the taxable income of other profit-making business activities, at the Company's discretion. The remaining taxable income, after such offset, shall be subject to the corporate income tax rate applicable to the business activities generating the taxable income, in accordance with Article 6 of Decree No. 320/2025/ND-CP dated 15 December 2025.

Value added tax

The goods sold and services rendered by the Company are subject to value added tax at the following rates:

- Applying a tax rate of 5% for medicinal drugs;
- Other activities: are applicable in accordance with the prevailing regulations.

Other taxes

Other taxes are applicable in accordance with the prevailing tax laws in Vietnam.

The tax reports of the Company will be inspected by the Tax Department. Application of the laws and regulations on tax to different transactions can be interpreted by many ways; therefore, the tax

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

amounts presented in the interim financial statements can be amended in accordance with the Tax Department's final assessment.

Deferred corporate income tax expense

Deferred corporate tax expense is determined on the basis of the deductible temporary differences, taxable temporary differences and the estimated CIT rate that will be applied for the years that assets and liabilities will be recovered. The tax rates used will be the tax rates (and tax laws) that are in effect at the financial year end.

Deferred tax liability is recognised for all taxable temporary differences, unless:

- The deferred tax liability arises from the initial recognition of an asset or liability in a transaction which at the time of the transaction, affects neither the accounting profit nor taxable profit (tax loss).
- All taxable temporary differences associated with investments in subsidiaries, branches and associates, and interests in joint ventures when the parent, investor or venturer is able to control the timing of the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future.

A deferred tax asset is recognised for all deductible temporary differences to the extent that it is probable that taxable profit will be available against which the deductible temporary difference can be utilised, unless:

- The deferred tax asset arises from the initial recognition of an asset or liability in a transaction which at the time of transaction, affects neither accounting profit nor taxable profit (tax loss).
- The deferred tax assets for all deductible temporary differences associated with investments in subsidiaries, branches and associates, and interests in joint ventures are only recognised when it is probable that the temporary difference will reverse in the foreseeable future; and taxable profit will be available against which the temporary difference can be utilised.

The carrying amount of a deferred tax asset shall be reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow the benefit of part or all of that deferred tax asset to be utilised. Any such reduction shall be reverted to the extent it becomes probable that sufficient taxable profit will be available.

Current and deferred tax are recognised as income or an expense and included in profit or loss for the year except to the extent that the tax arises from a transaction or event which is recognised, in the same or a different period, directly in equity.

Deferred tax assets and deferred tax liabilities are only offset if, and only if, the Company has a legally enforceable right to set off current tax assets against current tax liabilities and the deferred tax assets and the deferred tax liabilities relate to income taxes levied by the same taxation authority and the Company intends to settle current tax liabilities and assets on a net basis or to realise the assets and settle the liabilities simultaneously, in each future period in which significant amounts of deferred tax liabilities or assets are expected to be settled or recovered.

3.23. Earnings per share

Basic earnings per share are calculated by dividing the net profit attributable to ordinary shareholders (after adjusted for bonus and welfare funds), by the weighted average number of ordinary shares outstanding during the period, excluding ordinary shares bought back by the Company and held as treasury shares.

3.24. Diluted earnings per share

Diluted earnings per share are calculated by dividing the net profit attributable to ordinary shareholders (after adjusted for bonus and welfare funds), by the weighted average number of ordinary shares

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

outstanding during the period and total ordinary shares that would be issued on the conversion, excluding ordinary shares bought back by the Company and held as treasury shares.

3.25. Segement reporting

A segment is a distinguishable component of the Company that is engaged either in producing or providing related products or services (business segment), or in producing or providing products or services within a particular economic environment (geographical segment), which is subject to risks and rewards that are different from those of other segments.

Refer to section 7 in Notes to the interim financial statements.

3.26. Related parties

Related parties are individuals or entities that have the ability, directly or indirectly through one or more intermediaries, to control the Company or are controlled by, or are subject to common control with the Company. Associates, individuals owning, directly or indirectly, an interest in the voting power of the Company that gives them significant influence over the Company, key management personnel, including directors and officers of the Company and close family members or associates of such individuals are also considered to be related parties.

4. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE INTERIM FINANCIAL POSITION STATEMENT

4.1. Cash and cash equivalents

	Foreign currencies	As at 30 Jun. 2026 VND	Foreign currencies	As at 01 Jan. 2026 VND
Cash in hand		372,078,900		356,169,155
- VND		323,248,186		307,726,694
- USD	1,857.67 #	48,830,714	1,857.67 #	48,442,461
Cash at banks		6,753,962,648		68,635,246,774
- VND		6,654,923,521		14,267,193,556
<i>In which:</i>				
+ Vietnam Joint Stock Commercial Bank for Industry and Trade - Danang branch		1,445,612,714		9,066,883,642
+ Vietnam Technological and Commercial Joint Stock Bank - Danang branch		2,691,958,406		807,133,162
+ Vietnam Bank for Agriculture and Rural Development - Danang branch		1,171,528,577		1,156,728,154
+ Other banks		1,345,823,824		3,236,448,598
- USD	939.37 #	24,675,604	612.86 #	15,950,240
- EUR	2,464.36 #	74,363,523	1,790,921.47 #	54,352,102,978
Cash equivalents		54,417,832,408		-
- 1 month term deposits (EUR)	1,800,000.00 #	54,365,400,000		-
- Accrued interest		52,432,408		-
Total		61,543,873,956		68,991,415,929

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.2. Current trade receivables

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	VND		VND	
	Value	Provision	Value	Provision
Danhson - BG Ltd	105,186,767,429	-	245,319,144,115	-
Kim Do Pharmacy Co.,Ltd	-	-	4,094,628,132	-
Danhson Trading VN Co.,Ltd	-	-	206,272,840	-
Others	139,890,574,756	4,783,253,162	133,386,034,349	4,594,439,971
Total	245,077,342,185	4,783,253,162	383,006,079,436	4,594,439,971
In which: Trade Receivables from related parties	105,201,767,429	-	245,550,416,955	-
- Refer to Notes 8				

4.3. Current advances to suppliers

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	VND		VND	
	Value	Provision	Value	Provision
Joy - Maitreya Int'l Ltd	16,186,543,200	16,186,543,200	16,186,543,200	11,330,580,240
Bao Nguyen Chau Group JSC	-	-	9,231,774,529	-
GREENSOL Company Limited	-	-	6,268,766,087	-
Others	33,890,608,062	-	27,620,647,914	-
Total	50,077,151,262	16,186,543,200	59,307,731,730	11,330,580,240

4.4. Other receivables

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	VND		VND	
	Value	Provision	Value	Provision
Advance	4,721,141,349	-	5,688,003,672	-
Deposits	228,836,195	-	310,536,525	-
Other receivables	2,326,572,681	-	380,739,175	15,212,183
Total	7,276,550,225	-	6,379,279,372	15,212,183
In which: Other Receivables from related parties - Refer to Notes 8	301,308,170	-	-	-

NOTES TO INTERIM THE FINANCIAL STATEMENTS (CONTINUED)

4.5. Doubtful debts

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	VND		VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Overdue trade receivables or overdue amounts loaned and other receivables not yet due but uncollectible	33,804,834,363	12,835,038,001	25,574,628,824	9,634,396,430
Total	33,804,834,363	12,835,038,001	25,574,628,824	9,634,396,430

Overdue trade receivables and overdue amounts loaned are analysed by debtor as follows:

	As at 30 Jun. 2026			As at 01 Jan. 2026		
	VND			VND		
	Cost	Recoverable amount	Overdue days	Cost	Recoverable amount	Overdue days
State Pharmaceutical Company Limited	109,122,583	-	Over 3 years	109,122,583	-	Over 3 years
- Quang Ngai Medical Supplies						
Phuong Anh Pharmacy	79,843,635	-	Over 3 years	79,843,635	-	Over 3 years
Dong Thap Mental Hospital	458,076,400	320,653,480	From 6 months to 1 year	1,407,035,200	984,924,640	From 6 months to 1 year
Dong Thap Mental Hospital	-	-	Recovered	246,642,000	123,321,000	From 1 to 2 years
Others	33,157,791,745	12,514,384,521	Over 6 months	23,731,985,406	8,526,150,790	Over 6 months
Total	33,804,834,363	12,835,038,001		25,574,628,824	9,634,396,430	

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.6. Inventories

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	VND		VND	
	Cost	Provision	Cost	Provision
Raw materials	80,933,638,863	3,663,436,052	75,318,503,012	4,367,965,385
Tools	300,951,311	-	318,139,156	-
Work in progress	11,856,744,150	-	15,725,654,311	-
Finished goods	77,047,359,179	207,040,136	43,586,405,409	820,979,722
Merchandise	1,365,363,478	-	-	-
Total	171,504,056,981	3,870,476,188	134,948,701,888	5,188,945,107

Slow moving and obsolescent inventories at the period- end amounted to VND 3,870,476,188.

The company is pledging its entire inventory to secure bank loans.

4.7. Deferred expenses

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Current:		
Office rental expenses	1,670,772,873	125,787,991
Tools waiting for allocation	2,568,020,812	1,402,959,509
Insurance expense	253,956,211	45,811,085
Others	279,174,742	747,085,075
Total	4,771,924,638	2,321,643,660
Non-current:		
Land rental in Tan Tao industrial park	11,557,318,080	11,797,262,400
Others	3,682,808,174	3,408,055,847
Total	15,240,126,254	15,205,318,247

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.8. Non-current Financial investments

Other investments are detailed as follows:

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	Cost	Recoverable amount VND	Cost	Recoverable amount VND
Investments in associates:				
Davina Pharmaceutical Joint Stock Company	8,820,000,000	-	8,820,000,000	-
Total	8,820,000,000		8,820,000,000	8,820,000,000

The situation of affiliate company activities in the period:

Davina Pharmaceutical Joint Stock Company

Business operations suffered losses

Business operations suffered losses

According to the Minutes of the Extraordinary General Meeting of Shareholders 2025 No. 02/2025/BB-DHDCD dated 31 July 2025, the Company has approved the policy to transfer all shares of Davina Pharmaceutical Joint Stock Company to interested partners and investors.

As at the reporting date, the Company has not yet determined the recoverable amount of the investment in Davina Pharmaceutical Joint Stock Company for disclosure in the financial statements because there is no market quotation, and Vietnamese Accounting Standards and the Vietnamese Corporate Accounting System do not yet provide guidance or calculation methods for the selling price of the investment. The recoverable amount of this investment may differ from its original cost.

	As at 30 Jun. 2026		As at 01 Jan. 2026	
	Cost	Recoverable amount VND	Cost	Recoverable amount VND
Investments in other entities:				
Danang Pharmaceutical Medical Equipment JSC	6,800,000,000	9,007,284,000	6,800,000,000	7,852,504,000
Total	6,800,000,000	9,007,284,000	6,800,000,000	7,852,504,000

As at the reporting date, the Company has not yet determined the value in use of the investment in Danang Pharmaceutical Medical Equipment Joint Stock Company because Vietnamese Accounting Standards and the Vietnamese Corporate Accounting System do not yet provide guidance on how to calculate the value in use; therefore, the recoverable amount of the investment in Danang Pharmaceutical Medical Equipment Joint Stock Company is determined based on the fair value of the investment in Danang Pharmaceutical-Medical Equipment Joint Stock Company, relying on the market price quoted on the stock exchange and the number of shares held by the Company, less estimated costs to sell.

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

The company has determined the fair value of the investment in Danang Pharmaceutical Medical Equipment JSC based on the listed price on the stock exchange and the number of shares the company currently holds. The fair value as at 30 June 2026 and 01 January 2026 of Danang Pharmaceutical Medical Equipment JSC is determined based on the number of shares held and the closing price on the UPCOM trading platform on the respective dates. As at 30 June 2026: Number of shares held: 1,154,780 shares; Closing price: 7,800 VND/share. As at 31 December 2025: Number of shares held: 1,154,780 shares; Closing price: 6,800 VND/share.

4.9. Tangible fixed assets

Items	Buildings, structures VND	Machinery and equipment VND	Motor vehicles VND	Total VND
Cost:				
As at 01 Jan. 2026	144,571,793,790	215,239,263,528	15,316,904,578	375,127,961,896
Self-construction	385,278,149,364	347,148,105,543	4,653,982,333	737,080,237,240
Purchase	-	586,288,519	633,001,345	1,219,289,864
Disposals	-	(2,194,373,375)	(975,627,273)	(3,170,000,648)
As at 30 Jun. 2026	529,849,943,154	560,779,284,215	19,628,260,983	1,110,257,488,352
Accumulated depreciation:				
As at 01 Jan. 2026	108,244,843,891	194,997,622,289	11,426,234,906	314,668,701,086
Depreciation	6,494,803,410	15,149,398,450	550,111,371	22,194,313,231
Disposals	-	(2,194,373,375)	(975,627,273)	(3,170,000,648)
As at 30 Jun. 2026	114,739,647,301	207,952,647,364	11,000,719,004	333,693,013,669
Net book value:				
As at 01 Jan. 2026	36,326,949,899	20,241,641,239	3,890,669,672	60,459,260,810
As at 30 Jun. 2026	415,110,295,853	352,826,636,851	8,627,541,979	776,564,474,683

The amount of period-end net book value of tangible fixed assets totalling VND 19,718,286,431 was pledged/mortgaged as loan security.

The historical cost of tangible fixed assets fully depreciated but still in use at the end of the period totalled VND 172,389,414,003.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.10. Intangible fixed assets

Items	Land use rights VND	Total VND
Cost:		
As at 01 Jan. 2026	48,689,386,013	48,689,386,013
Purchase	-	-
As at 30 Jun. 2026	48,689,386,013	48,689,386,013
Accumulated amortization:		
As at 01 Jan. 2026	13,442,961,481	13,442,961,481
Amortization	465,275,556	465,275,556
As at 30 Jun. 2026	13,908,237,037	13,908,237,037
Net book value:		
As at 01 Jan. 2026	35,246,424,532	35,246,424,532
As at 30 Jun. 2026	34,781,148,976	34,781,148,976

The land use rights in Nam Long Residential Area, part of Nam Can Tho Urban Area, Hung Thanh Ward, Cai Rang Ward, Can Tho City, on land parcel number 1244, map sheet number 07, with an area of 114 m², are certified by the Certificate of Land Use Right, Ownership of Residential House, and Attached Assets on Land number CG 823962 issued by the Department of Natural Resources and Environment of Can Tho City on 19 May 2017. The land is designated for residential purposes in urban areas, with a long-term duration of use. The land use rights are currently mortgaged to secure a short-term loan at Vietnam Technological and Commercial Joint Stock Bank - Da Nang Branch.

The land use rights at Lot A24, Nguyen Van Linh Extended Road, Hai Chau Ward, Da Nang City, on land parcel number 1, map sheet A24, with an area of 616.8 m², are certified by the Certificate of Land Use Right, Ownership of Residential House, and Attached Assets on Land number BE 572297 issued by the People's Committee of Da Nang City on 21 July 2011. The land is designated for production and business purposes, with a duration of 50 years starting from 21 July 2011. This land use right is mortgaged as collateral for a loan from the Development Investment Fund Da Nang City.

The land use rights in Nam Ngan Ward, Thanh Hoa City, Thanh Hoa Province, on land parcel number 282, map sheet number 49, with an area of 240 m², are certified by the Certificate of Land Use Right, Ownership of Residential House, and Attached Assets on Land number CG 188553 issued by the Department of Natural Resources and Environment of Thanh Hoa Province on 14 February 2017. The land is designated for residential purposes in urban areas, with a long-term duration of use. The land use rights are currently mortgaged to secure a short-term loan at Commercial Bank for Foreign Trade of Vietnam – Danang Branch.

The amount of period-end net book value of intangible fixed assets totalling VND 34,781,148,976 was pledged/mortgaged as loan security.

There are no intangible fixed assets fully depreciated but still in use at the end of the period.

4.11. Construction in progress

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center	638,079,171,770	1,312,500,531,193
Office and Tourist Apartment Complex (Danapha Tower)	107,785,903,364	91,579,319,637
Other construction	1,345,767,221	1,345,767,221
Total	747,210,842,355	1,405,425,618,051

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.12. Trade payables

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Current:		
Danhson - BG Ltd	92,765,370,500	72,145,826,400
METECNO Viet Nam Limited Company	6,253,263,542	9,182,517,856
Refrigeration Electrical Engineering Bach Khoa Co.Ltd	5,276,045,667	27,729,514,986
Toan Phuc Pharmaceutical Chemical Co. Ltd	9,383,079,930	6,481,797,000
Others	69,862,903,390	84,339,832,077
Total	183,540,663,029	199,879,488,319
Non-current:		
Danhson - BG Ltd	217,784,327,145	328,383,111,022
Total	217,784,327,145	328,383,111,022
In which: Trade payables to related parties - Refer to Notes 8	310,936,461,395	402,383,519,561

4.13. Current advances from customers

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Tu Hung Pharmaceutical Company Limited	1,359,466,290	1,521,450,000
Danhson Trading VN Co.,Ltd	2,291,706,526	-
DY Traders Company Limited (formerly Duc Hanh Supermarket one member Co.Ltd)	200,000,000	200,000,000
Hiep Thuan Thanh Medical Co.Ltd	2,525,545,050	-
Others	1,325,153,162	185,370,492
Total	7,701,871,028	1,906,820,492
In which: Advances from customers are related parties - Refer to Notes 8	2,291,706,526	-

4.14. Dividends and profit distribution payable

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Dividends payable for 2022	3,185,000	3,185,000
Dividends payable for other years	6,905,920	6,905,920
Total	10,090,920	10,090,920

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.15. Tax and amounts receivable from/payable to the state budget

	As at 30 Jun. 2026		Movement in the period		As at
	VND		VND		01 Jan. 2026
	Receivable	Payable	Payable	Paid/ Deducted	VND
VAT on domestic goods	-	-	12,187,438,547	12,187,438,547	-
VAT on imported goods	-	-	2,973,776,970	2,973,776,970	-
Export, import tax	9,128,881	-	181,164,291	190,293,172	-
Corporate Income Tax	-	20,182,896,987	23,907,492,017	18,381,066,861	14,656,471,831
Personal Income Tax	-	3,943,127,350	11,495,001,874	9,503,369,383	1,951,494,859
Property tax and land lease payments	-	1,527,900,874	3,055,801,749	1,527,900,875	-
Other taxes	-	-	2,469,433,815	2,469,433,815	-
Total	9,128,881	25,653,925,211	56,270,109,263	47,233,279,623	16,607,966,690

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.16. Payables to employees

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Salaries and bonuses payables to employees	23,124,594,413	32,408,028,038
Total	23,124,594,413	32,408,028,038

4.17. Current accrued expenses

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Interest payable	218,088,562	126,268,287
Accrued selling expenses	24,304,978,728	33,350,399,971
Others	1,498,298,330	1,059,116,251
Total	26,021,365,620	34,535,784,509

4.18. Other current payables

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Trade Union fees	63,050,900	56,556,486
Interest payable	8,866,355,655	32,281,883,973
Others	2,754,231,339	413,230,398
Total	11,683,637,894	32,751,670,857
In which: Other payables to related parties - Refer to Notes 8	8,734,180,085	32,280,740,850

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.19. Loans and finance lease liabilities

	As at 30 Jun. 2026		Movement in the period		As at 01 Jan. 2026	
	VND		VND		VND	
	Value	Payable value	Increase	Decrease	Value	Payable value
Current:						
Joint Stock Commercial Bank for Foreign Trade of Vietnam - Da Nang Branch (1)	-	-	-	44,736,044,389	44,736,044,389	44,736,044,389
Vietnam Joint Stock Commercial Bank for Industry and Trade - Da Nang Branch (2)	38,518,229,453	38,518,229,453	52,518,229,453	33,308,247,397	19,308,247,397	19,308,247,397
Vietnam Technological and Commercial Joint Stock Bank - Da Nang Branch (3)	18,011,361,372	18,011,361,372	40,231,437,943	43,161,328,712	20,941,252,141	20,941,252,141
Joint Stock Commercial Bank for Investment and Development of Vietnam (4)	6,317,497,099	6,317,497,099	6,317,497,099	-	-	-
Vietnam Bank for Agriculture and Rural Development - Da Nang Branch (5)	96,893,078,336	96,893,078,336	135,770,585,569	138,762,244,928	99,884,737,695	99,884,737,695
Current portion of non-current loans:						
Danhson - BG Ltd (EUR) (6)	225,742,500,000	225,742,500,000	237,735,000,000	11,992,500,000	-	-
Danang Development and Investment Fund (9)	17,645,800,000	17,645,800,000	11,186,400,000	5,517,200,000	11,976,600,000	11,976,600,000
Total	403,128,466,260	403,128,466,260	483,759,150,064	277,477,565,426	196,846,881,622	196,846,881,622
Non-current:						
Danhson - BG Ltd (EUR) (6)	-	-	-	237,735,000,000	237,735,000,000	237,735,000,000
Ms. Pham Huong Giang (7)	78,649,999,990	78,649,999,990	-	-	78,649,999,990	78,649,999,990
Ms. Nguyen Phuong Vy (8)	63,464,336,093	63,464,336,093	-	-	63,464,336,093	63,464,336,093
Danang Development and Investment Fund (9)	150,302,800,000	150,302,800,000	60,353,000,000	11,186,400,000	101,136,200,000	101,136,200,000
Total	292,417,136,083	292,417,136,083	60,353,000,000	248,921,400,000	480,985,536,083	480,985,536,083
In which: Long-term loan from related parties – Refer to Notes 8	142,114,336,083	142,114,336,083	-	237,735,000,000	379,849,336,083	379,849,336,083

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

- (1) Short-term loan from Joint Stock Commercial Bank for Foreign Trade of Vietnam – Danang Branch (Vietcombank – Danang Branch) under Credit Contract No. 48/2025/CTD/VCB-KHDN dated 13 March 2025. The purpose of the loan is to supplement working capital for business operations, with a credit limit of VND 50,000,000,000.
- (2) Short-term loan at Vietnam Joint Stock Commercial Bank for Industry and Trade - Danang Branch under Contract No. 2400000954/2025-HDCVHM/NHCT480-DANAPHA dated 03 October 2025 to supplement working capital for pharmaceutical production and related products with a total loan balance of VND 150,000,000,000. The loan is secured by company-owned raw materials and machinery and equipment, with interest rates specified in each promissory note.
- (3) Short-term loan from Vietnam Technological and Commercial Joint Stock Bank – Danang Branch under Credit Agreement No. DNG20171436/HDTD, signed on 30 September 2017, and its attached appendices dated 13 February 2026, 21 April 2026, and 28 May 2026 to supplement working capital for the production and business of pharmaceutical products, with a credit limit of VND 110,000,000,000. The loan is secured by land use rights and assets attached to the land in Can Tho under Mortgage Contract No. DNG202013286338/HDTC, inventories at the Can Tho branch under Mortgage Contract No. DNG202013286338/HDTC, and fixed assets under Mortgage Contract No. DNG202113291809/HDTC.
- (4) Short-term loan from the Joint Stock Commercial Bank for Investment and Development of Vietnam – Danang Branch under Credit Contract No. 01/2025/256857/HDTD signed on 31 July 2025 to supplement working capital, provide guarantees, and open Letters of Credit (L/C), with a credit limit of VND 40,000,000,000. The interest rate is specified in each Promissory Note.
- (5) Short-term loan from Vietnam Bank for Agriculture and Rural Development – Danang Branch (Agribank – Danang Branch) under Credit Contract No. 2000-LAV-202400779, signed on 30 July 2025, and Appendix No. 102025/2000-LAV-202400779 dated 24 October 2025 to supplement working capital to implement the business and production plan for the period 2025–2026, with a credit limit of VND 100,000,000,000, and interest rates determined per each Promissory Note. The collateral includes a purified water generation system and a distilled water generation system under Asset Mortgage Agreement No. 2000-LCL-202500084 dated 19 March 2025, and an R&D line, an automatic inhaler tube filling machine line, and an automatic balm box packaging machine under Mortgage Agreement No. 2000-LCL-202500319 dated 30 July 2025.
- (6) Long-term loan for DANHSON-BG LTD under Loan contract No. 01/2022/DNP-DS dated 01 May 2022 with a term of 5 years from 01 May 2022 to 01 May 2027 for the purpose of purchasing machinery and equipment for the Project Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center with a credit limit of EUR 7,500,000 and an interest rate of 3.5%. The company will repay the principal in full on 01 May 2027.
- (7) Long-term loan from Ms. Pham Huong Giang under Contract dated 19 September 2024, with a maximum loan term of 10 years from the date of receipt of the loan, loan amount: VND 135,000,000,000 and Contract dated 17 March 2025, with a maximum loan term of 10 years from the date of receipt of the loan, loan amount: VND 90,000,000,000. The purpose of the loan is to serve the Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center project, and to serve the Company's production and business operations. The loan interest rate is 6.3%/year for the first year. The principal will be repaid after 5 years from the loan date or repaid in multiple installments within the loan term as agreed. The loan contract dated 19 September 2024, has been terminated according to the loan reconciliation and loan agreement termination record dated 30 November 2024. However, the company is still obligated to pay interest and principal as outlined in the signed loan contract.

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

- (8) Long-term loan from Ms. Nguyen Phuong Vy under Contract dated 19 September 2024, with a maximum loan term of 10 years from the date of receipt of the loan, loan amount: VND 120,000,000,000 and Contract dated 17 March 2025, with a maximum loan term of 10 years from the date of receipt of the loan, loan amount: VND 15,000,000,000. The purpose of the loan is to serve for the Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center project, and to serve the Company's production and business operations. The loan interest rate is 6.3%/year for the first year. The principal will be repaid after 5 years from the loan date or repaid in multiple installments within the loan term as agreed. The loan contract dated 19 September 2024, has been terminated according to the loan reconciliation and loan agreement termination record dated 30 November 2024. However, the company is still obligated to pay interest and principal as outlined in the signed loan contract.
- (9) Loan from the Development Investment Fund under Credit contract No. 14/2024/HDTĐ, dated 29 May 2024, and Amendment No. 14/2025/HDTĐ dated 31 March 2025, with a loan amount of VND 80,000,000,000 and a loan term of 96 months. The purpose of the loan is to finance the investment costs for the project of a Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center. The interest rate is 6.5% per annum, as per Decision No. 552/QĐ-TTĐ dated 24 December 2024, the interest rate has been adjusted to 5.6% per annum. The loan is secured by future-formed assets, including the entire construction works of the Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center project, and Land Use Rights Certificate No. 06 at Danang High-Tech Park.
- Loan from the Development Investment Fund under Credit contract No. 16/2025/HDTĐ dated 17 September 2025, with a loan amount of VND 90,000,000,000 and a loan term of 132 months. The purpose of the loan is to pay for investment costs of the Office and Tourist Apartment Complex project; the borrower commits to using the loan proceeds for the agreed purposes, and not for any other or unlawful purposes. The interest rate is 6.1% per annum. The loan is secured by land use rights and assets attached to land, which are construction works to be formed in the future of the financed project.
- Loan from the Development Investment Fund under Credit contract No. 02/2025/HDTĐ dated 26 December 2025, with a loan amount of VND 120,000,000,000 and a loan term of 108 months. The purpose of the loan is to pay for investment costs of the Pharmaceutical Manufacturing Plant and High-Tech Research and Development Center project; the borrower commits to using the loan proceeds for the agreed purposes, and not for any other or unlawful purposes. The interest rate is 5.6% per annum. The loan is secured by land use rights and assets attached to land, which are construction works to be formed in the future of the financed project.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)**4.20. Bonus and welfare fund**

	Current period VND
Beginning balance	1,371,022,612
Addition during the period	-
Utilisation during the period	(63,459,039)
Ending balance	1,307,563,573

4.21. Deferred income tax liabilities

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Deferred income tax liabilities:		
Income tax rate used to calculate deferred income tax liabilities	20%	20%
Deferred tax liabilities relating to the taxable temporary differences	740,149,323	5,267,768,728
Offset against deferred tax assets	(493,549,528)	(631,958,303)
Total	246,599,795	4,635,810,425

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)**4.22. Owners' equity****4.22.1. Changes in owners' equity**

	Items of owners' equity				Total VND
	Owners' contributed capital VND	Capital surplus VND	Investment and development fund VND	Retained earnings VND	
As at 01 Jan. 2025	209,380,000,000	181,169,607,584	304,136,126,279	70,241,659,293	764,927,393,156
Previous period's profits	-	-	-	24,545,902,078	24,545,902,078
Distributed investment and development fund	-	-	69,998,059,293	(69,998,059,293)	-
As at 30 Jun. 2025	209,380,000,000	181,169,607,584	374,134,185,572	24,789,502,078	789,473,295,234
Profit in the last 6 months of the previous year	-	-	-	61,203,650,650	61,203,650,650
As at 01 Jan. 2026	209,380,000,000	181,169,607,584	374,134,185,572	85,993,152,728	850,676,945,884
Current period's profits	-	-	-	70,689,574,828	70,689,574,828
Distributed investment and development fund (*)	-	-	85,993,152,728	(85,993,152,728)	-
As at 30 Jun. 2026	209,380,000,000	181,169,607,584	460,127,338,300	70,689,574,828	921,366,520,712

(*) The Company distributed profits of the year 2025 in accordance with the Resolution of the General Meeting of Shareholders 2026 No. 01/2026/NQ-DHDCD dated 31 March 2026.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.22.2. Details of owners' equity

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
DANHSON VN Company Limited	148,604,730,000	148,604,730,000
Vietnam Pharmaceutical Corporation - JSC	55,381,670,000	55,381,670,000
Other shareholders	5,393,600,000	5,393,600,000
Total	209,380,000,000	209,380,000,000

4.22.3. Capital transactions with owners

	Current period VND	Previous period VND
Beginning balance	209,380,000,000	209,380,000,000
Capital contribution in the year	-	-
Capital redemption in the year	-	-
Ending balance	209,380,000,000	209,380,000,000

4.22.4. Shares

	As at 30 Jun. 2026	As at 01 Jan. 2026
Number of shares registered for issue	20,938,000	20,938,000
Number of shares sold to public	20,938,000	20,938,000
- <i>Ordinary shares</i>	20,938,000	20,938,000
- <i>Preference shares (Classified as owners' equity)</i>	-	-
Number of shares repurchased (Treasury shares)	-	-
- <i>Ordinary shares</i>	-	-
- <i>Preference shares (Classified as owners' equity)</i>	-	-
Number of shares outstanding	20,938,000	20,938,000
- <i>Ordinary shares</i>	20,938,000	20,938,000
- <i>Preference shares (Classified as owners' equity)</i>	-	-

Par value per outstanding share: VND 10,000 per share

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.22.5. Basic earnings per share

	Current period VND	Previous period VND
Profit after tax	70,689,574,828	24,545,902,078
Adjusted for distribution to bonus and welfare fund	-	-
Earnings for the purpose of calculating basic earnings per share	70,689,574,828	24,545,902,078
Weighted average number of ordinary shares outstanding during the period	20,938,000	20,938,000
Basic earnings per share	3,376	1,172

The company's charter and the 2026 annual general meeting of shareholders' resolution do not specify the rate for distribution to the bonus and welfare fund. Accordingly, the profit after corporate income tax used to calculate the basic earnings per share for this period is the company's entire after-tax profit attributable to shareholders. These figures may change if the company decides to allocate funds in the future.

4.22.6. Diluted earnings per share

	Current period VND	Previous period VND
Net profit after tax	70,689,574,828	24,545,902,078
Adjusted for distribution to bonus and welfare fund	-	-
Adjustments to increase/decrease profit after tax	-	-
Earnings for the purpose of calculating diluted earnings per share	70,689,574,828	24,545,902,078
Average Number of shares outstanding in year	20,938,000	20,938,000
Number of common shares expected to be issued	-	-
Number of shares to calculate diluted earnings per share	20,938,000	20,938,000
Diluted earnings per share	3,376	1,172

The company's charter and the 2026 annual general meeting of shareholders' resolution do not specify the rate for distribution to the bonus and welfare fund. Accordingly, the profit after corporate income tax used to calculate the Diluted earnings per share for this period is the company's entire after-tax profit attributable to shareholders. These figures may change if the company decides to allocate funds in the future.

4.22.7. Corporate funds

	Investment and Development fund VND
As at 01 Jan. 2026	374,134,185,572
Additions	85,993,152,728
Utilisations	-
As at 30 Jun. 2026	460,127,338,300

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

4.23. Off-Interim financial position statement items

	As at 30 Jun. 2026	As at 01 Jan. 2026
Foreign currencies:		
+ USD	2,797.04	2,470.53
+ EUR	1,802,464.36	1,790,921.47

5. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE INTERIM INCOME STATEMENT

5.1. Revenue from selling goods and rendering services

	Current period VND	Previous period VND
Sale of merchandise, finished goods	328,919,193,309	295,891,820,513
Revenue from rendering of services	109,090,914	105,757,580
Total	329,028,284,223	295,997,578,093
Of which revenue from selling goods and rendering services to related parties – Refer to Note 8	150,566,791,323	100,916,852,855

5.2. Deductions

	Current period VND	Previous period VND
Sales returns	2,575,781,083	476,462,003
Sales allowances	-	901,608,619
Total	2,575,781,083	1,378,070,622
Revenue deductions arising from transactions with related parties – Refer to Note 8	1,623,720,000	-

5.3. Cost of sales

	Current period VND	Previous period VND
Cost of merchandise sold and finished goods sold	146,473,063,641	132,313,250,442
Provision for decline in value of inventories/ Reversals of provision for decline in value of inventories	(291,792,480)	965,600,012
Total	146,181,271,161	133,278,850,454

5.4. Finance income

	Current period VND	Previous period VND
Deposit interest	378,984,100	650,433,261
Gains from exchange differences	17,883,925,199	3,098,637,800
Total	18,262,909,299	3,749,071,061

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

5.5. Finance expense

	Current period VND	Previous period VND
Interest expense	9,581,105,054	3,914,351,333
Losses from exchange differences in payment	570,292,748	28,349,077,195
Total	10,151,397,802	32,263,428,528

5.6. Selling expense

	Current period VND	Previous period VND
Staff expenses	10,533,112,766	13,180,598,529
Material, package, tools expense	52,212,451	20,527,310
Depreciation expense	515,638,408	434,383,737
Expenses for outsourced services	2,687,948,984	2,193,289,978
Other expenses	26,756,168,290	33,724,916,537
Total	40,545,080,899	49,553,716,091

5.7. General and administrative expense

	Current period VND	Previous period VND
Staff expenses	29,474,014,892	26,627,680,189
Raw materials, tools and instruments	2,370,076,437	4,225,460,201
Depreciation expense	5,163,777,895	3,225,395,179
Expenses for outsourced services	7,453,634,661	6,214,574,256
Provision expenses for bad debts	5,029,563,968	2,051,732,830
Other expenses	8,323,428,280	10,878,347,940
Total	57,814,496,133	53,223,190,595

5.8. Other income

	Current period VND	Previous period VND
Income from disposal of fixed assets	264,755,980	-
Others	83,500,607	106,363,848
Total	348,256,587	106,363,848

5.9. Other expense

	Current period VND	Previous period VND
Penalties	163,560,610	18,237,052
Others	6,206	49,554,563
Total	163,566,816	67,791,615

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

5.10. Production and business costs by element

	Current period VND	Previous period VND
Raw materials, tools and instruments	132,675,927,731	121,432,373,249
Staff expenses	61,550,491,373	52,083,911,911
Depreciation expense	22,659,588,787	8,463,880,336
Expenses for outsourced services	18,476,592,834	11,082,213,301
Other expenses	35,812,478,897	47,228,035,379
Total	271,175,079,622	240,290,414,176

5.11. Current corporate income tax expense

	Current period VND	Previous period VND
Accounting profit before tax	90,207,856,215	30,087,965,097
Add: Adjustments according to CIT law	26,577,671,057	4,755,436,405
- Gains on exchange rate differences due to revaluation at the end of the previous year's period	22,638,097,026	-
- Losses on exchange rate differences due to revaluation at the end of this year's period	2,467,747,642	-
- Remuneration The Board of Directors does not directly participate in management	526,762,563	514,409,043
- Expenses not deductible for tax purposes	945,063,826	4,241,027,362
Less: Adjustments according to CIT law	9,919,737,168	28,331,574,550
- Income subjected to additional corporate income tax of previous years	6,759,945,655	-
- Gains on exchange rate differences due to revaluation at the end of the current year	-	24,356,441,125
- Losses on exchange rate differences due to revaluation at the end of the previous year, that are deductible when calculating corporate income tax in the current year	3,159,791,513	1,409,779,425
- Expenses not deductible for tax purposes in previous year that are deductible when calculating corporate income tax in the current year	-	2,565,354,000
Total taxable income	106,865,790,105	6,511,826,952
Corporate income tax rate	20%	20%
Current corporate income tax expense	23,907,492,017	1,317,035,226
In which:		
CIT expenses are calculated on annual taxable income current year	21,373,158,021	1,302,365,390
Adjust previous years' corporate income tax expenses to this year's current income tax expenses	2,534,333,996	14,669,836

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

5.12. Deferred corporate income tax expense

	Current period VND	Previous period VND
Deferred corporate income tax expense arising from temporary taxable difference	(3,895,661,102)	4,871,288,225
Deferred corporate income tax income arising from temporary deductible differences	(493,549,528)	(646,260,432)
Deferred corporate income tax expense	(4,389,210,630)	4,225,027,793

6. ADDITIONAL INFORMATION FOR ITEMS SHOWN IN THE INTERIM CASH FLOW STATEMENT

6.1. Cash receipts from loans in the period

	Current period VND	Previous period VND
Cash receipts from loans under normal contracts	295,190,750,064	290,739,684,078
Total	295,190,750,064	290,739,684,078

6.2. Cash repayments of principal amounts borrowed

	Current period VND	Previous period VND
Cash repayment of principal amounts under normal contracts	265,485,065,426	172,547,679,763
Total	265,485,065,426	172,547,679,763

7. SEGMENT REPORTING

For management purposes, the Company divides its operations nationwide into key departments according to geographical regions as follows:

- Headquarters
- Sales Department
- Ho Chi Minh City Branch
- Ha Noi Branch
- Thanh Hoa Branch
- Khanh Hoa Branch
- Vinh Phuc Branch
- Can Tho Branch

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

For the six months ended 30 June 2026:

The first six months of 2026	Headquarters VND	Sales	Ho Chi Minh VND	Ha Noi VND	Thanh Hoa VND	Vinh Phuc VND	Khanh Hoa VND	Can Tho VND	Total VND
		Department VND							
Revenue	153,361,962,142	23,718,108,943	40,886,626,227	35,208,560,675	20,228,667,960	13,934,834,674	12,357,738,878	29,331,784,724	329,028,284,223
+ External	153,361,962,142	23,718,108,943	40,886,626,227	35,208,560,675	20,228,667,960	13,934,834,674	12,357,738,878	29,331,784,724	329,028,284,223
+ Inter-segment	-	-	-	-	-	-	-	-	-
Deductions	1,623,720,000	36,344,571	278,539,904	340,835,285	153,797,524	32,839,495	39,622,627	70,081,677	2,575,781,083
Net revenue	151,738,242,142	23,681,764,372	40,608,086,323	34,867,725,390	20,074,870,436	13,901,995,179	12,318,116,251	29,261,703,047	326,452,503,140
Cost of sales	75,989,970,443	13,732,597,432	14,138,179,115	13,140,034,389	8,585,000,329	5,102,163,581	4,846,727,489	10,646,598,383	146,181,271,161
Gross profit	75,748,271,699	9,949,166,940	26,469,907,208	21,727,691,001	11,489,870,107	8,799,831,598	7,471,388,762	18,615,104,664	180,271,231,979

The first six months

of 2026	Headquarters VND	Sales		Ho Chi Minh VND	Ha Noi VND	Thanh Hoa VND	Vinh Phuc VND	Khanh Hoa VND	Can Tho VND	Total VND
		Department VND								
Cost of purchasing assets	188,634,968,099	-	-	-	-	-	-	-	-	188,634,968,099
Depreciation expense	21,141,853,203	-	1,303,436,482	93,900,876	-	-	-	66,338,226	54,060,000	22,659,588,787

	Headquarters VND	Sales		Ho Chi Minh VND	Ha Noi VND	Thanh Hoa VND	Vinh Phuc VND	Khanh Hoa VND	Can Tho VND	Total VND
		Department VND								
As at 30 Jun. 2026										
Segment assets	182,926,415,855	13,986,988,550	34,976,290,564	28,564,124,110	14,715,855,709	13,292,949,342	9,617,177,686	29,366,955,992	327,446,757,808	
Unallocated assets									1,786,540,003,875	
T total assets									2,113,986,761,683	
Segment liabilities	9,251,853,981	3,543,247,975	5,979,396,078	4,410,276,910	3,005,079,767	1,960,836,708	1,604,949,322	3,967,595,907	33,723,236,648	
Unallocated liabilities									1,158,897,004,323	
T total liabilities									1,192,620,240,971	

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

	Headquarters VND	Sales Department VND	Ho Chi Minh VND	Ha Noi VND	Thanh Hoa VND	Vinh Phuc VND	Khanh Hoa VND	Can Tho VND	Total VND
As at 01 Jan. 2026									
Segment assets	293,610,765,884	13,982,232,271	28,251,069,580	26,905,985,784	13,573,910,172	10,993,559,115	10,568,472,669	35,061,198,722	432,947,194,197
Unallocated assets									1,748,051,963,276
Total assets	3,021,677,211	4,639,416,190	7,094,161,915	6,338,034,427	5,114,717,235	2,584,876,616	1,929,372,879	5,720,348,528	2,180,999,157,473
Segment liabilities									36,442,605,001
Unallocated liabilities									1,293,879,606,588
Total liabilities									1,330,322,211,589

For the six months ended 30 June 2025:

	Headquarters VND	Sales Department VND	Ho Chi Minh VND	Ha Noi VND	Thanh Hoa VND	Vinh Phuc VND	Khanh Hoa VND	Can Tho VND	Total VND
The first six months of 2025									
Revenue	112,883,296,303	22,774,756,628	47,775,378,808	37,414,828,847	22,635,968,593	11,573,850,076	11,992,378,968	28,947,119,870	295,997,578,093
+ External	112,883,296,303	22,774,756,628	47,775,378,808	37,414,828,847	22,635,968,593	11,573,850,076	11,992,378,968	28,947,119,870	295,997,578,093
+ Inter-segment	-	-	-	-	-	-	-	-	-
Deductions	964,764,723	2,366,019	34,304,362	38,830,239	30,919,509	4,000,000	17,935,714	284,950,056	1,378,070,622
Net revenue	111,918,531,580	22,772,390,609	47,741,074,446	37,375,998,608	22,605,049,084	11,569,850,076	11,974,443,254	28,662,169,814	294,619,507,471
Cost of sales	70,077,486,028	8,626,853,532	16,053,632,691	11,824,473,361	8,078,817,289	3,584,746,217	4,196,640,472	10,836,200,864	133,278,850,454
Gross profit	41,841,045,552	14,145,537,077	31,687,441,755	25,551,525,247	14,526,231,795	7,985,103,859	7,777,802,782	17,825,968,950	161,340,657,017

	Headquarters VND	Sales Department VND	Ho Chi Minh VND	Ha Noi VND	Thanh Hoa VND	Vinh Phuc VND	Khanh Hoa VND	Can Tho VND	Total VND
The first six months of 2025									
Cost of purchasing assets	100,444,250,212	-	-	-	-	-	-	-	100,444,250,212
Depreciation expense	6,935,689,966	-	1,348,473,510	-	-	-	125,656,860	54,060,000	8,463,880,336

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

8. RELATED PARTIES

<u>List of related parties</u>	<u>Relationship</u>
1. Danhson VN Limited Company	Parent Company
2. Vietnam Pharmaceutical Corporation - JSC	Investment company
3. Danhson - BG Ltd	Same key management personnel
4. Danhson Trading VN Ltd	Same key management personnel
5. Vetprom AD	Subsidiary of Danhson - BG Ltd
6. Ms. Nguyen Phuong Vy	Related person of the Parent Company
7. Ms. Pham Huong Giang	Related person of the Parent Company
8. Board of Directors and management	Key management personnel

At the date of preparation of the interim statement of financial position, the balances of receivables, payables and loans with related parties are as follows:

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Trade receivables		
Danhson VN Company limited	15,000,000	25,000,000
Danhson - BG Ltd	105,186,767,429	245,319,144,115
Danhson Trading VN Company limited	-	206,272,840
Total - Refer to Note 4.2	105,201,767,429	245,550,416,955

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Other receivables		
Vetprom AD	301,308,170	-
Total - Refer to Note 4.4	301,308,170	-

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Trade payables		
Danhson - BG Ltd	310,549,697,645	400,528,937,422
Vetprom AD	386,763,750	1,854,582,139
Total - Refer to Note 4.12	310,936,461,395	402,383,519,561

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Advance from customer		
Danhson Trading VN Company limited	2,291,706,526	-
Total - Refer to Note 4.13	2,291,706,526	-

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Long-term loan		
Danhson - BG Ltd	225,742,500,000	237,735,000,000
Ms. Pham Huong Giang	78,649,999,990	78,649,999,990
Ms. Nguyen Phuong Vy	63,464,336,093	63,464,336,093
Total - Refer to Note 4.19	367,856,836,083	379,849,336,083

	As at 30 Jun. 2026 VND	As at 01 Jan. 2026 VND
Interest on loans payable		
Danhson - BG Ltd	3,918,023,852	28,725,497,227
Ms. Pham Huong Giang	1,903,659,969	2,835,359,387
Ms. Nguyen Phuong Vy	2,912,496,264	719,884,236
Total - Refer to Note 4.18	8,734,180,085	32,280,740,850

During the period, the Company has had related party transactions as follows:

	Current period VND	Previous period VND
Selling goods and rendering services		
Danhson VN Company Limited	27,272,727	23,939,394
Danhson - BG Ltd	83,046,341,751	59,723,587,519
Danhson Trading VN Company limited	67,493,176,845	41,169,325,942
Total - Refer to Note 5.1	150,566,791,323	100,916,852,855

	Current period VND	Previous period VND
Deductions		
Danhson Trading VN Company limited	1,623,720,000	-
Total - Refer to Note 5.2	1,623,720,000	-

	Current period VND	Previous period VND
Purchase of goods, services		
Vietnam Pharmaceutical Corporation - JSC	166,330,372	105,407,191
- Trademark usage fees	166,330,372	105,407,191
Vetprom AD	391,871,532	-
Danhson - BG Ltd	1,020,013,500	135,650,301,150
Danhson Trading VN Company limited	-	31,727,960
Total	1,186,343,872	135,787,436,301

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

	Current period VND	Previous period VND
Danhson - BG Ltd		
Interest expense	3,988,506,181	3,786,959,388
	Current period VND	Previous period VND
Ms. Pham Huong Giang		
Loan - Refer to note 4.19	-	57,350,000,000
Interest expense (before PIT withholding)	2,681,350,582	1,117,214,384
Pay Interest expense (before PIT withholding)	3,613,050,000	-
	Current period VND	Previous period VND
Ms. Nguyen Phuong Vy		
Interest expense (before PIT withholding)	2,192,612,028	1,847,639,274
Pay Interest expense (before PIT withholding)	-	-

Remunerations of the Management Board and Supervisory Board (before PIT withholding):

Name	Position		Current period VND	Previous period VND
Mr. Bojinov Stefan Georgiev	Chairman of the BODs	Reappointed on 31 March 2026	750,000,000	750,000,000
Mr. Dobrev Sasho Hristov	Member of the BODs	Reappointed on 31 March 2026	375,000,000	375,000,000
Mr. Le Thang Binh	Member of the BODs	Reappointed on 31 March 2026	461,538,462	461,538,462
Mr. Do Minh Hieu	Member of the BODs	Reappointed on 31 March 2026	87,514,037	91,365,096
Ms. Nguyen Thuy Dung	Member of the BODs	Dismissed on 31 July 2025	-	53,333,332
Mr. Pham Thai Lang	Independent Member of the BODs	Dismissed on 31 July 2025	-	68,484,847
Ms. Nguyen Thanh Thao	Independent Member of the BODs	Reappointed on 31 March 2026	79,999,998	79,999,998
Ms. Nguyen Thi Thuy	Member of the BODs	Reappointed on 31 March 2026	79,999,998	79,999,998
Ms. Ha Lan Anh	Member of the BODs	Reappointed on 31 March 2026	79,999,998	-
Ms. Do Thi Thuy	Independent Member of the BODs	Reappointed on 31 March 2026	79,999,998	-
Mr. Ngo Xuan Tung	Head of Supervisory Committee	Reappointed on 31 March 2026	98,960,582	106,006,524
Ms. Nguyen Thi Yen Nhi	Member of Supervisory Committee	Reappointed on 31 March 2026	37,562,689	36,635,340
Ms. Luu Quynh Mai	Member of Supervisory Committee	Reappointed on 31 March 2026	40,000,002	40,000,002

Salaries, bonuses and other incomes of the General Directors, Management Board (before PIT withholding):

Name	Position	Classification of income	Current period VND	Previous period VND
Mr. Bojinov Stefan Georgiev	Chairman of the BODs	Salary	144,500,000	120,000,000
Mr. Dobrev Sasho Hristov	Member of the BODs	Salary	214,200,000	180,000,000
Name	Position	Classification of income	Current period VND	Previous period VND
Mr. Le Thang Binh	General Director	Salaries and other benefits	1,191,252,921	952,800,000
		Bonuses for exceeding profit targets (*)	7,000,000,000	

(*) Bonuses for exceeding the 2025 profit target (implemented in accordance with Resolution No. 21/2024/NQ-HĐQT dated 8 July 2024).

DANAPHA PHARMACEUTICAL JOINT STOCK COMPANY

Address: 253 Dung Si Thanh Khe Street, Thanh Khe Ward, Da Nang City, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)**9. COMMITMENT UNDER OPERATING LEASES**

The Company leases land under operating lease contracts; the land lease term is according to the lease contracts, with rent recorded during the period:

	Current period VND	Previous period VND
Operating rental costs (Land lease expense) recorded during the year	1,703,502,312	1,697,332,824

As at 30 June 2026, the Company has outstanding commitments under non-cancellable operating leases that fall due as follows:

	As at 30 Jun. 2026	As at 01 Jan. 2026
Within one year	3,040,882,411	3,394,665,647
Later than one year but within five years	2,899,077,899	4,589,512,443
Later than five years	4,419,302,806	4,433,469,332
Total	10,359,263,116	12,417,647,422

The payments for lease activities mentioned above include:

Total rental and infrastructure usage fees at Hoa Khanh Industrial Park, Da Nang City under Lease Agreement No. 51/HĐTLĐ with an amount of VND 29,266,906 per month. The lease agreement is signed for a term of 40 years from 01 November 2003 to 01 November 2043.

Total rental fees for land at 253 Dung Si Thanh Khe, Thanh Khe Ward, Danang City, according to the Decision to extend the lease period No. 246/QĐ-UBND dated 20 January 2025, the extension period to 11 January 2028. According to Notification No. 6112/TB-DAN dated 08 July 2026 issued by the Da Nang City Tax Department, the land rental rate was adjusted to VND 129,517 per m² per year; accordingly, the total rental is VND 2,689,679,539 per year (VND 224,139,962 per month).

10. COMPARATIVE FIGURES

As disclosed in Note 3.1, the Company's interim financial statements for the accounting period ended 30 June 2026 have been prepared and presented in accordance with Circular 99. Accordingly, certain comparative figures have been reclassified to conform with the presentation requirements of the interim financial statements for the period ended 30 June 2026 due to the adoption of Circular 99, as follows:

Items	Code	As at 01 Jan. 2026 (restated) VND	Reclassification under Circular No. 99 VND	As at 01 Jan. 2026 (previously reported) VND
Dividends and profit distribution payable	313	10,090,920	10,090,920	-
Other current payables	320	32,751,670,857	132,462,600	32,619,208,257
Subsidised funds	431	-	(142,553,520)	142,553,520

NOTES TO THE INTERIM FINANCIAL STATEMENTS (CONTINUED)

11. EVENTS AFTER THE END OF THE REPORTING PERIOD

According to Official Letter No. 7206/UBCK-GSDC dated 31 July 2026, the State Securities Commission of Vietnam announced the cancellation of the public company status for the Company effective from 31 July 2026.

Besides the above event, there were no significant events arising after the end of the reporting period to the date of the interim financial statements.



Le Thang Binh
General Director
Danang City, 14 August 2026

Tran Tien Dung
Chief Financial Officer Cum
Chief Accountant

Nguyen Thi Thu Hang
Preparer